Navigation Links
HUYA Bioscience International Forms Alliance With Zhejiang Chinese Medical University Life Science College

SAN DIEGO, Calif., Sept. 8, 2011 /PRNewswire/ -- HUYA Bioscience International, a leader in globalizing China's pharmaceutical innovations, today announced a strategic partnership with the Zhejiang Chinese Medical University Life Science College. The collaboration agreement will accelerate the global drug development of China's novel Traditional Chinese Medicines (TCM).

The partnership is expected to bring productive synergy between the two parties. Zhejiang Chinese Medical University Life Science College, a prominent traditional Chinese medicine university in southern China, is recognized for its strength in leading-edge research in TCM.  HUYA has a strong commitment toward developing novel therapeutics from TCM in areas of unmet medical needs.  HBI-3000, HUYA's novel anti-arrhythmic compound currently in development in both China and the U.S., was originally derived from a TCM.

HUYA is one of the first companies to have recognized China's potential to help meet the global need for new preclinical and clinical stage compounds. The company is committed to facilitating and promoting the global development and commercialization of novel pharmaceutical products originating in China. HUYA has established a series of collaborations with leading universities and research institutions throughout China and has pioneered in-licensing innovative compounds from the country, utilizing its expertise to advance these compounds for global markets.

"The alliance with Zhejiang Chinese Medical University Life Science College will further strengthen HUYA's collaborative efforts with the faculty and researchers of the university," said Clement Gingras, HUYA's CTO and COO, China. "Together, HUYA and Zhejiang Chinese Medical University Life Science College will help advance the progression of TCM to the global markets, benefiting patients worldwide."

Dr. Zhishan Ding, Associate Dean of Zhejiang Chinese Medical University Life Science College, commented, "Our College is dedicated to promoting TCM innovations. We are delighted to collaborate with HUYA and together we will share the commitment towards the global development of novel therapeutics from TCM in areas of unmet medical need."


HUYA is the leader in global pharmaceutical co-development with Chinese partners. With seven offices strategically located in China, the most comprehensive Chinese compound portfolio, and a rapidly growing number of exclusive agreements with premier Chinese research and development organizations, HUYA is uniquely positioned to identify and license novel Chinese compounds. HUYA offers Western pharmaceutical companies efficient access to innovative therapeutic opportunities and helps to reduce deal-making complexity in China. The company has become a champion of guiding China's biomedical innovations to the worldwide marketplace. HUYA has joint headquarter offices in San Diego, CA, USA and Shanghai, China. Additional information about the company is available at


Zhejiang Chinese Medical University Life Science College, established in April 2000, is a successor of the Institute of Molecular Medicine. The college has six research departments: Biochemistry, Genetics and Molecular Biology, Cell Biology, Microbiology and Immunology, General Biology, and Clinical Laboratory Science. With well-defined missions, elite faculty, and outstanding educational subjects, Zhejiang Chinese Medical University Life Science College is now a leading institute for TCM in China. It has received various awards, developed two new drugs (one successfully marketed), undertaken a significant number of projects, and published numerous papers. For more information, please visit


Yung-Chih Wang, Ph.D., MBA
Vice President, Corporate Development, China
HUYA Bioscience International

Qing (Vicky) Xia, MS, MBA
Senior Business Development Manager
HUYA Bioscience International

SOURCE HUYA Bioscience International
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Ardea Biosciences Announces Positive End-of-Phase 2 Meetings with FDA for Lesinurad
2. Avantra Biosciences Changes Company Name to Courtagen Life Sciences, Inc.
3. BD Biosciences Announces Winners of Research Grant Program
4. 3-V Biosciences Appoints George W. Kemble, PhD, as Chief Scientific Officer
5. Numira Biosciences Names New Board Member
6. Ardea Biosciences Reports Recent Accomplishments and Second Quarter 2011 Financial Results
7. Amarantus BioSciences and Generex Biotechnology Collaborate on Cell Therapy for Late Stage Diabetes
8. BioMed Realty Trust and BIND Biosciences Sign New Lease at Vassar Street Property
9. Neurocrine Biosciences Reports Second Quarter 2011 Results
10. Sangamo BioSciences Reports Second Quarter 2011 Financial Results
11. Roka Bioscience Participates in the International Association for Food Protection Conference
Post Your Comments:
(Date:11/26/2015)... 26, 2015 --> ... in imaging technologies, announced today that it has received a ... the Horizon 2020 European Union Framework Programme for Research and ... trial in breast cancer. , --> ... --> --> The study aims to ...
(Date:11/25/2015)... 2015 Studies reveal the differences ... and pave the way for more effective treatment for one ...   --> --> ... problems in cats, yet relatively little was understood about the ... have been conducted by researchers from the WALTHAM Centre for ...
(Date:11/25/2015)... ... 25, 2015 , ... A long-standing partnership between the Academy ... been formalized with the signing of a Memorandum of Understanding. , AMA Executive ... Karl Minter and Capt. Albert Glenn Tuesday, November 24, 2015, at AMA Headquarters ...
(Date:11/24/2015)... LUMPUR, Malaysia , Nov. 24, 2015 /PRNewswire/ ... global contract research organisation (CRO) market. The trend ... result in lower margins but higher volume share ... increased capacity and scale, however, margins in the ... Research Organisation (CRO) Market ( ), ...
Breaking Biology Technology:
(Date:11/9/2015)... ) ... "Global Law Enforcement Biometrics Market 2015-2019" ... ) has announced the addition of ... 2015-2019" report to their offering. ... ) has announced the addition of the ...
(Date:11/2/2015)... Calif. , Nov. 2, 2015  SRI International ... million to provide preclinical development services to the National ... contract, SRI will provide scientific expertise, modern testing and ... variety of preclinical pharmacology and toxicology studies to evaluate ... --> The PREVENT Cancer Drug Development Program ...
(Date:10/29/2015)... , Oct. 29, 2015 Daon, a ... that it has released a new version of its ... in North America have already ... v4.0 also includes a FIDO UAF certified server ... already preparing to activate FIDO features. These customers include ...
Breaking Biology News(10 mins):